New CAR NK Cell Therapy Shows Promise for Autoimmune Disease Treatment

This groundbreaking study from China demonstrates that allogeneic CAR NK-cell therapy could revolutionize treatment for autoimmune diseases like systemic lupus erythematosus (SLE). Unlike current approaches that modify patients' own immune cells, this therapy uses donor natural killer cells engineered to target problematic B cells, potentially offering safer and more accessible treatment.

Researchers treated 18 patients with severe, treatment-resistant SLE using three infusions of genetically modified NK cells over a treatment cycle. All patients had failed at least two standard therapies, including biological drugs. The treatment protocol included lymphodepleting chemotherapy followed by CAR NK-cell infusions at escalating doses.

Results were remarkably encouraging. Only one patient experienced mild cytokine release syndrome, and no serious therapy-related complications occurred. Among nine patients with over 12 months follow-up, six (67%) achieved DORIS remission and low disease activity states, representing significant clinical improvement in a notoriously difficult-to-treat condition.

For longevity and health optimization, this research suggests a future where autoimmune diseases—which can significantly impact healthspan and quality of life—might be more effectively controlled with safer cellular therapies. The allogeneic approach addresses key limitations of current CAR-T therapies, including manufacturing time, cost, and safety concerns.

However, this remains early-stage research with a small patient group and relatively short follow-up period. The long-term durability of responses and broader applicability across different autoimmune conditions require further investigation through larger, controlled trials.